ReNeuron Group PLC's (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott they've seen a 'rapid and profound' result in the first three patients of the second phase of clinical studies of its human retinal progenitor cells (hRPC).
''What we're seeing is hugely encouraging and I think the principal investigator will make that clear when he presents the data next weekend''.